Descripción de la empresa
Instil Bio, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the development of a pipeline comprising novel therapeutic candidates designed to address significant unmet medical needs. The company functions within the healthcare sector, specifically the biotechnology industry, a domain characterized by high research and development expenditures and long clinical trial timelines before potential market approval. According to available financial data, Instil Bio, Inc. carries a market capitalization of $57.31M, while the specific figures for annual revenue and employee count are not disclosed in the provided records. The relatively modest market cap of $57.31M, combined with the lack of reported revenue in the data, indicates that the company is likely in a pre-commercialization phase where value is derived primarily from intellectual property and clinical progress rather than current sales performance.
Salud financiera
The reported net income for the trailing twelve months stands at $-71,372,000, while EBITDA is recorded at $-52,373,000; the absence of revenue data suggests that the substantial negative net income is driven by heavy operating costs associated with clinical trials and research activities rather than operational inefficiencies relative to sales. Free cash flow for the period was $-133,371,000, indicating that the company is burning significant cash reserves to fund its development programs, which severely limits immediate financial flexibility without further capital raises. All three reported margins—gross margin, operating margin, and profit margin—are listed at 0.0%, a figure typical for early-stage biotechnology firms that have not yet generated commercial revenue to establish a profit base. Despite the negative earnings, the company holds $79.67M in cash against $84.92M in debt, resulting in a debt-to-equity ratio of 70.52, which suggests a highly leveraged balance sheet relative to its equity base. The current ratio is an exceptionally high 39.53, implying that short-term liquid assets vastly exceed short-term liabilities, a position often seen in biotech firms where cash balances are high relative to immediate obligations. Return on Equity is -50.4% and Return on Assets is -14.2%, metrics that reflect the dilution of shareholder value and asset efficiency caused by the net losses incurred during the company's development stage rather than poor management effectiveness.
Evaluación de valoración
The trailing twelve-month P/E ratio is not available due to the lack of positive earnings, whereas the forward P/E is listed at -0.58, a negative figure that precludes any standard analysis of earnings trajectory but signals that the market is pricing in future profitability expectations rather than current performance. The price-to-book ratio is 0.50, indicating that the market values the company's equity at half of its book value, which often reflects the speculative nature of assets held by clinical-stage companies that may not fully appear on the balance sheet. Alternative valuation metrics such as price-to-sales and EV/EBITDA are not applicable or show a negative EV/EBITDA of -1.19, suggesting that traditional multiple-based valuation models are not suitable for assessing this asset at this stage of development. The stock has exhibited significant volatility, with a 52-week high of $42.79 and a 52-week low of $5.67, meaning the current trading price exists within a range that reflects substantial price discovery and investor sentiment shifts. The beta of 2.03 indicates that the stock's price volatility is more than double that of the broader market, exposing investors to heightened systemic risk during periods of market stress.
Growth & Income
Revenue growth and earnings growth rates for the year-over-year period are not available in the provided data, preventing a direct comparison of earnings expansion relative to revenue generation which is common in mature companies. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that any generated earnings would theoretically be reinvested into growth initiatives or used to reduce debt rather than distributed to shareholders. This non-dividend policy is consistent with the operational profile of a clinical-stage biopharmaceutical company that must prioritize capital allocation toward advancing its pipeline candidates like AXN-2510/IMM2510. Consequently, the overall growth and income profile is defined entirely by potential future clinical successes and the ability to extend cash runway, rather than current cash flow generation or shareholder returns through dividends.